Quantitative expression analysis and prognostic significance of the BCL2-associated X gene in nasopharyngeal carcinoma: A retrospective cohort study

BMC Cancer

Volumn 13, Issue , 2013, Pages

  Kontos, Christos K ^a   Fendri, Ali ^b   Khabir, Abdelmajid ^c   Mokdad Gargouri, Raja ^b   Scorilas, Andreas ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b CENTRE DE BIOTECHNOLOGIE DE SFAX   (Tunisia)

^c HABIB BOURGUIBA HOSPITAL   (Tunisia)

Author keywords

Apoptosis; Head and neck cancer; Nasopharynx; Prognostic tumor biomarkers; Quantitative real time PCR

Indexed keywords

COMPLEMENTARY DNA; MESSENGER RNA; PROTEIN BAX; BAX PROTEIN, HUMAN; TRANSCRIPTOME; TUMOR MARKER;

ADOLESCENT; ADULT; AGE; AGED; ARTICLE; BAX GENE; CANCER RECURRENCE; CELL STRAIN HL 60; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DNA SYNTHESIS; ETHNIC GROUP; FEMALE; GENDER; GENE EXPRESSION; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; KAPLAN MEIER METHOD; LYMPH NODE; MAJOR CLINICAL STUDY; MALE; NASOPHARYNX CARCINOMA; OVERALL SURVIVAL; PROGNOSIS; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDY; REVERSE TRANSCRIPTION; RNA ISOLATION; SCHOOL CHILD; TUMOR BIOPSY; TUNISIAN; BIOSYNTHESIS; GENETICS; METABOLISM; MIDDLE AGED; NASOPHARYNX TUMOR; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

BCL-2-ASSOCIATED X PROTEIN; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NASOPHARYNGEAL NEOPLASMS; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TRANSCRIPTOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84879049484     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-13-293     Document Type: Article

References (64)

1. Kerr JF, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 1972, 26(4):239-257. 10.1038/bjc.1972.33, 2008650, 4561027.
2. Reed JC. Dysregulation of apoptosis in cancer. J Clin Oncol 1999, 17(9):2941-2953.
3. Evan GI, Vousden KH. Proliferation, cell cycle and apoptosis in cancer. Nature 2001, 411(6835):342-348. 10.1038/35077213, 11357141.
4. Reed JC. Mechanisms of apoptosis. Am J Pathol 2000, 157(5):1415-1430. 10.1016/S0002-9440(10)64779-7, 1885741, 11073801.
5. Zimmermann KC, Bonzon C, Green DR. The machinery of programmed cell death. Pharmacol Ther 2001, 92(1):57-70. 10.1016/S0163-7258(01)00159-0, 11750036.
6. Adams JM, Cory S. The Bcl-2 protein family: arbiters of cell survival. Science 1998, 281(5381):1322-1326.
7. Petros AM, Olejniczak ET, Fesik SW. Structural biology of the Bcl-2 family of proteins. Biochim Biophys Acta 2004, 1644(2-3):83-94.
8. Youle RJ, Strasser A. The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol 2008, 9(1):47-59. 10.1038/nrm2308, 18097445.
9. Korsmeyer SJ, Shutter JR, Veis DJ, Merry DE, Oltvai ZN. Bcl-2/Bax: a rheostat that regulates an anti-oxidant pathway and cell death. Semin Cancer Biol 1993, 4(6):327-332.
10. Shinoura N, Yoshida Y, Asai A, Kirino T, Hamada H. Relative level of expression of Bax and Bcl-XL determines the cellular fate of apoptosis/necrosis induced by the overexpression of Bax. Oncogene 1999, 18(41):5703-5713. 10.1038/sj.onc.1202966, 10523849.
11. Thomadaki H, Scorilas A. BCL2 family of apoptosis-related genes: functions and clinical implications in cancer. Crit Rev Clin Lab Sci 2006, 43(1):1-67. 10.1080/10408360500295626, 16531274.
12. Yip KW, Reed JC. Bcl-2 family proteins and cancer. Oncogene 2008, 27(50):6398-6406. 10.1038/onc.2008.307, 18955968.
13. Oltvai ZN, Milliman CL, Korsmeyer SJ. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 1993, 74(4):609-619. 10.1016/0092-8674(93)90509-O, 8358790.
14. Suzuki M, Youle RJ, Tjandra N. Structure of Bax: coregulation of dimer formation and intracellular localization. Cell 2000, 103(4):645-654. 10.1016/S0092-8674(00)00167-7, 11106734.
15. Zha H, Aime-Sempe C, Sato T, Reed JC. Proapoptotic protein Bax heterodimerizes with Bcl-2 and homodimerizes with Bax via a novel domain (BH3) distinct from BH1 and BH2. J Biol Chem 1996, 271(13):7440-7444. 10.1074/jbc.271.13.7440, 8631771.
16. Oltvai ZN, Korsmeyer SJ. Checkpoints of dueling dimers foil death wishes. Cell 1994, 79(2):189-192. 10.1016/0092-8674(94)90188-0, 7954787.
17. Yin XM, Oltvai ZN, Korsmeyer SJ. BH1 and BH2 domains of Bcl-2 are required for inhibition of apoptosis and heterodimerization with Bax. Nature 1994, 369(6478):321-323. 10.1038/369321a0, 8183370.
18. Meijerink JP, Mensink EJ, Wang K, Sedlak TW, Sloetjes AW, De Witte T, Waksman G, Korsmeyer SJ. Hematopoietic malignancies demonstrate loss-of-function mutations of BAX. Blood 1998, 91(8):2991-2997.
19. Chan AT, Teo PM, Johnson PJ. Nasopharyngeal carcinoma. Ann Oncol 2002, 13(7):1007-1015. 10.1093/annonc/mdf179, 12176778.
20. Vokes EE, Liebowitz DN, Weichselbaum RR. Nasopharyngeal carcinoma. Lancet 1997, 350(9084):1087-1091. 10.1016/S0140-6736(97)07269-3, 10213566.
21. Wei WI, Sham JS. Nasopharyngeal carcinoma. Lancet 2005, 365(9476):2041-2054. 10.1016/S0140-6736(05)66698-6, 15950718.
22. Busson P, Keryer C, Ooka T, Corbex M. EBV-associated nasopharyngeal carcinomas: from epidemiology to virus-targeting strategies. Trends Microbiol 2004, 12(8):356-360. 10.1016/j.tim.2004.06.005, 15276610.
23. Chang ET, Adami HO. The enigmatic epidemiology of nasopharyngeal carcinoma. Cancer Epidemiol Biomarkers Prev 2006, 15(10):1765-1777. 10.1158/1055-9965.EPI-06-0353, 17035381.
24. Feng BJ, Jalbout M, Ayoub WB, Khyatti M, Dahmoul S, Ayad M, Maachi F, Bedadra W, Abdoun M, Mesli S, et al. Dietary risk factors for nasopharyngeal carcinoma in Maghrebian countries. Int J Cancer 2007, 121(7):1550-1555. 10.1002/ijc.22813, 17582611.
25. Lo KW, To KF, Huang DP. Focus on nasopharyngeal carcinoma. Cancer Cell 2004, 5(5):423-428. 10.1016/S1535-6108(04)00119-9, 15144950.
26. Nicholls JM, Agathanggelou A, Fung K, Zeng X, Niedobitek G. The association of squamous cell carcinomas of the nasopharynx with Epstein-Barr virus shows geographical variation reminiscent of Burkitt's lymphoma. J Pathol 1997, 183(2):164-168. 10.1002/(SICI)1096-9896(199710)183:2<164::AID-PATH919>3.0.CO;2-J, 9390028.
27. Khabir A, Sellami A, Sakka M, Ghorbel AM, Daoud J, Frikha M, Drira MM, Busson P, Jlidi R. Contrasted frequencies of p53 accumulation in the two age groups of North African nasopharyngeal carcinomas. Clin Cancer Res 2000, 6(10):3932-3936.
28. Daoud J, Toumi N, Bouaziz M, Ghorbel A, Jlidi R, Drira MM, Frikha M. Nasopharyngeal carcinoma in childhood and adolescence: analysis of a series of 32 patients treated with combined chemotherapy and radiotherapy. Eur J Cancer 2003, 39(16):2349-2354. 10.1016/S0959-8049(03)00512-4, 14556927.
29. Cammoun M, Hoerner V, Mourali N. Tumors of the nasopharynx in Tunisia. An anatomic and clinical study based on 143 cases. Cancer 1974, 33(1):184-192. 10.1002/1097-0142(197401)33:1<184::AID-CNCR2820330127>3.0.CO;2-T, 4810092.
30. Chan JY, Chow VL, Mok VW, Ho AC, Wei WI. Prediction of surgical outcome using plasma epstein-barr virus dna and (18) F-FDG PET-CT scan in recurrent nasopharyngeal carcinoma. Head Neck 2012, 34(4):541-545. 10.1002/hed.21768, 21523844.
31. Lin S, Tham IW, Pan J, Han L, Chen Q, Lu JJ. Combined High-dose Radiation Therapy and Systemic Chemotherapy Improves Survival in Patients With Newly Diagnosed Metastatic Nasopharyngeal Cancer. Am J Clin Oncol 2012, 35(5):474-479. 10.1097/COC.0b013e31821a9452, 21577086.
32. Tulalamba W, Janvilisri T. Nasopharyngeal carcinoma signaling pathway: an update on molecular biomarkers. International journal of cell biology 2012, 2012:594681. 3303613, 22500174.
33. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001, 25(4):402-408. 10.1006/meth.2001.1262, 11846609.
34. Korbakis D, Scorilas A. Treatment of gastric cancer cells with 5-fluorouracil/leucovorin and irinotecan induces distinct alterations in the mRNA expression of the apoptosis-related genes, including the novel gene BCL2L12. Tumour Biol 2009, 30(2):100-107. 10.1159/000218160, 19440006.
35. Altman DG, Lausen B, Sauerbrei W, Schumacher M. Dangers of using "optimal" cutpoints in the evaluation of prognostic factors. J Natl Cancer Inst 1994, 86(11):829-835. 10.1093/jnci/86.11.829, 8182763.
36. Camp RL, Dolled-Filhart M, Rimm DL. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res 2004, 10(21):7252-7259. 10.1158/1078-0432.CCR-04-0713, 15534099.
37. Cox DR. Regression models and life tables. R Stat Soc B 1972, 34:187-202.
38. Al-Sarraf M, LeBlanc M, Giri PG, Fu KK, Cooper J, Vuong T, Forastiere AA, Adams G, Sakr WA, Schuller DE, et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. J Clin Oncol 1998, 16(4):1310-1317.
39. Cheng SH, Tsai SY, Yen KL, Jian JJ, Chu NM, Chan KY, Tan TD, Cheng JC, Hsieh CY, Huang AT. Concomitant radiotherapy and chemotherapy for early-stage nasopharyngeal carcinoma. J Clin Oncol 2000, 18(10):2040-2045.
40. Pan Y, Claret FX. Targeting Jab1/CSN5 in nasopharyngeal carcinoma. Cancer Lett 2012, 326(2):155-160. 10.1016/j.canlet.2012.07.033, 22867945.
41. Fendri A, Khabir A, Hadhri-Guiga B, Sellami-Boudawara T, Ghorbel A, Daoud J, Frikha M, Jlidi R, Gargouri A, Mokdad-Gargouri R. Overexpression of COX-2 and LMP1 are correlated with lymph node in Tunisian NPC patients. Oral Oncol 2008, 44(7):710-715. 10.1016/j.oraloncology.2007.09.006, 18061524.
42. Fendri A, Masmoudi A, Khabir A, Sellami-Boudawara T, Daoud J, Frikha M, Ghorbel A, Gargouri A, Mokdad-Gargouri R. Inactivation of RASSF1A, RARbeta2 and DAP-kinase by promoter methylation correlates with lymph node metastasis in nasopharyngeal carcinoma. Cancer Biol Ther 2009, 8(5):444-451. 10.4161/cbt.8.5.7686, 19221469.
43. Guo X, Liao Q, Chen P, Li X, Xiong W, Ma J, Luo Z, Tang H, Deng M, Zheng Y, et al. The microRNA-processing enzymes: Drosha and Dicer can predict prognosis of nasopharyngeal carcinoma. J Cancer Res Clin Oncol 2012, 138(1):49-56. 10.1007/s00432-011-1058-1, 21953080.
44. Li XM, Huang WG, Yi H, Cheng AL, Xiao ZQ. Proteomic analysis to identify cytokeratin 18 as a novel biomarker of nasopharyngeal carcinoma. J Cancer Res Clin Oncol 2009, 135(12):1763-1775. 10.1007/s00432-009-0623-3, 19529960.
45. Chen LC, Hsueh C, Tsang NM, Liang Y, Chang KP, Hao SP, Yu JS, Chang YS. Heterogeneous ribonucleoprotein k and thymidine phosphorylase are independent prognostic and therapeutic markers for nasopharyngeal carcinoma. Clin Cancer Res 2008, 14(12):3807-3813. 10.1158/1078-0432.CCR-08-0155, 18559600.
46. Cui RX, Liu N, He QM, Li WF, Huang BJ, Sun Y, Tang LL, Chen M, Jiang N, Chen L, et al. Low BRMS1 expression promotes nasopharyngeal carcinoma metastasis in vitro and in vivo and is associated with poor patient survival. BMC Cancer 2012, 12(1):376. 10.1186/1471-2407-12-376, 3517767, 22931099.
47. Shackleford TJ, Claret FX. JAB1/CSN5: a new player in cell cycle control and cancer. Cell division 2010, 5:26. 10.1186/1747-1028-5-26, 2976740, 20955608.
48. Hector S, Prehn JH. Apoptosis signaling proteins as prognostic biomarkers in colorectal cancer: a review. Biochim Biophys Acta 2009, 1795(2):117-129.
49. Lindner AU, Concannon CG, Boukes GJ, Cannon MD, Llambi F, Ryan D, Boland K, Kehoe J, McNamara DA, Murray F, et al. Systems analysis of BCL2 protein family interactions establishes a model to predict responses to chemotherapy. Cancer Res 2013, 73(2):519-528. 10.1158/0008-5472.CAN-12-2269, 23329644.
50. Fendri A, Kontos CK, Khabir A, Mokdad-Gargouri R, Ardavanis A, Scorilas A. Quantitative analysis of BCL2 mRNA expression in nasopharyngeal carcinoma: an unfavorable and independent prognostic factor. Tumour Biol 2010, 31(5):391-399. 10.1007/s13277-010-0047-3, 20514538.
51. Chen MK, Yang SF, Lai JC, Yeh KT, Yang JS, Chen LS, Chen HC. Expression of bcl-2 correlates with poor prognosis and modulates migration of nasopharyngeal carcinoma cells. Clin Chim Acta 2010, 411(5-6):400-405.
52. Chen MK, Lai JC, Chang CC, Chang JH, Chang YJ, Chen HC. Prognostic impact of bcl-2 expression on advanced nasopharyngeal carcinoma. Head Neck 2008, 30(8):1052-1057. 10.1002/hed.20839, 18442057.
53. Vera-Sempere FJ, Burgos JS, Botella MS, Morera C. Immunohistochemical expression of Bcl-2 oncoprotein in EBV-associated nasopharyngeal carcinoma correlated to histological type and survival. Histol Histopathol 1997, 12(1):9-18.
54. Shinoura N, Yoshida Y, Nishimura M, Muramatsu Y, Asai A, Kirino T, Hamada H. Expression level of Bcl-2 determines anti- or proapoptotic function. Cancer Res 1999, 59(16):4119-4128.
55. Cheng EH, Kirsch DG, Clem RJ, Ravi R, Kastan MB, Bedi A, Ueno K, Hardwick JM. Conversion of Bcl-2 to a Bax-like death effector by caspases. Science 1997, 278(5345):1966-1968. 10.1126/science.278.5345.1966, 9395403.
56. Kolluri SK, Zhu X, Zhou X, Lin B, Chen Y, Sun K, Tian X, Town J, Cao X, Lin F, et al. A short Nur77-derived peptide converts Bcl-2 from a protector to a killer. Cancer Cell 2008, 14(4):285-298. 10.1016/j.ccr.2008.09.002, 2667967, 18835031.
57. Lin B, Kolluri SK, Lin F, Liu W, Han YH, Cao X, Dawson MI, Reed JC, Zhang XK. Conversion of Bcl-2 from protector to killer by interaction with nuclear orphan receptor Nur77/TR3. Cell 2004, 116(4):527-540. 10.1016/S0092-8674(04)00162-X, 14980220.
58. Fendri A, Kontos CK, Khabir A, Mokdad-Gargouri R, Scorilas A. BCL2L12 is a novel biomarker for the prediction of short-term relapse in nasopharyngeal carcinoma. Mol Med 2011, 17(3-4):163-171. 3060983, 21152697.
59. Reed JC. Balancing cell life and death: bax, apoptosis, and breast cancer. J Clin Invest 1996, 97(11):2403-2404. 10.1172/JCI118684, 507322, 8647929.
60. Zhang M, Li X, Zhang Y, Zhou K. Bax inhibitor-1 mediates apoptosis-resistance in human nasopharyngeal carcinoma cells. Mol Cell Biochem 2010, 333(1-2):1-7.
61. Lo YM, Chan LY, Lo KW, Leung SF, Zhang J, Chan AT, Lee JC, Hjelm NM, Johnson PJ, Huang DP. Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nasopharyngeal carcinoma. Cancer Res 1999, 59(6):1188-1191.
62. Grimm T, Schneider S, Naschberger E, Huber J, Guenzi E, Kieser A, Reitmeir P, Schulz TF, Morris CA, Sturzl M. EBV latent membrane protein-1 protects B cells from apoptosis by inhibition of BAX. Blood 2005, 105(8):3263-3269. 10.1182/blood-2004-07-2752, 15613549.
63. Bose P, Klimowicz AC, Kornaga E, Petrillo SK, Waynematthews T, Chandarana S, Magliocco AM, Brockton NT, Dort JC. Bax expression measured by AQUA analysis is an independent prognostic marker in oral squamous cell carcinoma. BMC Cancer 2012, 12(1):332. 10.1186/1471-2407-12-332, 3487960, 22852863.
64. Farkas R, Pozsgai E, Bellyei S, Cseke L, Szigeti A, Vereczkei A, Marton S, Mangel L, Horvath OP, Papp A. Correlation between tumor-associated proteins and response to neoadjuvant treatment in patients with advanced squamous-cell esophageal cancer. Anticancer Res 2011, 31(5):1769-1775.